Compare TG Therapeutics Inc (TGTX) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vipshop Holdings Ltd - ADR — how do they compare? TG Therapeutics Inc trades at $49.57 (market cap $7.64B), while Vipshop Holdings Ltd - ADR trades at $14.44 (market cap $7.20B). The key difference: TG Therapeutics Inc and Vipshop Holdings Ltd - ADR are close in size by market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VIPS | |
|---|---|---|
Market Cap | $7.64B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $20.68 |
52-Week Low | $26.94 | $12.92 |
Enterprise Value | $7.84B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
VIPS stock trades at $14.31, down 7.14% over 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 EPS of $0.68, meeting expectations, and maintains strong profitability with a net income margin of 7.07%. Recent news highlights growth initiatives, including an outlet strategy to boost performance amid industry challenges.
The outlook for VIPS is cautiously optimistic, supported by low valuation multiples like a P/E of 6.79 and a buy consensus from 53.57% of analysts. Risks include revenue stagnation and macroeconomic pressures, but the stock's discounted valuation may offer upside if growth resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
